SynKIR-310 for Relapsed/Refractory B-NHL
Phase 1
18
about 4.2 years
18+
5 sites in CO, GA, KS +2
What this study is about
Researchers are testing the safety and preliminary effectiveness of SynKIR-310, a medication given intravenously, in adults with relapsed or refractory B-cell non-Hodgkin lymphoma. The trial will last approximately 1521 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive SynKIR-310
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Recommended Phase 2 Dose (RP2D)
Secondary: PK profile of SynKIR-310, Preliminary efficacy : Objective response rate (ORR), Preliminary efficacy: Complete response rate (CR), Preliminary efficacy: Duration of response (DOR)
Oncology